Correction: Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells (Cancer Research (2006) 66 (1491-9) DOI: 10.1158/0008-5472.CAN-05-2514);Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1491-1499

  Todaro, Matilde ^a   Zerilli, Monica ^a   Ricci Vitiani, Lucia ^c   Bini, Miriam ^a   Alea, Mileidys Perez ^a   Florena, Ada Maria ^b   Miceli, Laura ^b   Condorelli, Gerolama ^d   Bonventre, Sebastiano ^a   Di Gesù, Giuseppe ^a   De Maria, Ruggero ^c,e   Stassi, Giorgio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Istituto Oncologico Del Mediterraneo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; CASPASE 8; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; PROTEIN PEA 15; PROTEIN PED; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION; THYROID CANCER; UPREGULATION;

EID: 32944465821     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2905     Document Type: Erratum

References (47)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
2. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
3. Walczak II, Sprick MR. Biochemistry and function of the DISC. Trends Biochem Sci 2001;26:452-3.
4. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993;5:625-30.
5. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
6. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-88.
7. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
8. Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-21.
9. Siegmund D, Mauri D, Peters N, et al. Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway. J Biol Chem 2001;276:32585-90.
10. Condorelli G, Vigliotta G, Cafieri A, et al. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999;18:4409-15.
11. Hao C, Beguinot F, Condorelli G, et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001;61:1162-70.
12. Brezniceanu ML, Volp K, Bosser S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003;17:1295-7.
13. Irisarri M, Plumas J, Bonnefoix T, et al. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia 2000;14:2149-58.
14. Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041-52.
15. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002;277:25020-5.
16. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-56.
17. Bartolazzi A, Gasbarri A. Thyroid disease classification. Lancet 2000;356:2010-1.
18. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW, Baker JR, Jr. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4246-52.
19. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:4122-9.
20. Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab 2001;12:384-90.
21. Poulaki V, Mitsiades CS, Kotoula V, et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002;161:643-54.
22. Tourneur L, Mistou S, Michiels FM, et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003;22:2795-804.
23. Stassi G, Todaro M, Zerilli M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003;63:6784-90.
24. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005;92:921-8.
25. Conticello C, Pedini F, Zeuner A. et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 2004;172:5467-77.
26. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003;22:7981-8.
27. Haque SJ, Harbor PC, Williams BR. Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling. J Biol Chem 2000;275:26500-6.
28. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-κB in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005;64:160-7.
29. Rahaman SO, Vogelbaum MA, Haque SJ. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Rα2. Cancer Res 2005;65:2956-63.
30. Nitta T, Hishii M, Sato K, Okumura K. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 1994;649:122-8.
31. Sredni B, Weil M, Khomenok G, et al. Ammonium trichloro(dioxoethylene-o, o′)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 2004;64:1843-52.
32. Stassi G, Todaro M, Bucchieri F, et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J Immunol 1999;162:263-7.
33. Stassi G, Di Liberto D, Todaro M, et al. Control of target cells survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol 2000;1:1-6.
34. Ricci-Vitiani L, Pedini F, Mollinari C, et al. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J Exp Med 2004;200:1257-66.
35. Yoshida T, Ogata H, Kamio M, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004;199:1701-7.
36. Todaro M, Zerilli M, Triolo G, et al. NF-κB protects Behcet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 2005;52:2179-91.
37. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002;12:309-15.
38. Reed CJ. Apoptosis and cancer: strategies for integrating programmed cell death. Semin Hematol 2000;37:9-16.
39. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2002;2:195-204.
40. Stassi G, Zeuner A, Di Liberto D, Todaro M, Ricci-Vitiani L, De Maria R. Fas-FasL in Hashimoto's thyroiditis. J Clin Immunol 2001;21:19-23.
41. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
42. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994;180:1961-6.
43. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-6.
44. Weiner HL. Induction and mechanism of action of transforming growth factor-β- secreting Th3 regulatory cells. Immunol Rev 2001;182:207-14.
45. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-26.
46. Wurster AL, Rodgers VL, White MF, Rothstein TL, Grusby MJ. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002;277:27169-75.
47. Wurster AL, Withers DJ, Uchida T, White MF, Grusby MJ. Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4-dependent rescue from apoptosis. Mol Cell Biol 2002;22:117-26.